Why Clovis Oncology Inc Shares Could Bounce Back to $50

While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense.

What: Shares of Clovis Oncology Inc (NASDAQ: CLVS  ) surged 7% today after Stifel upgraded the biopharmaceutical company from hold to buy.

So what: Along with the upgrade, analyst Brian Klein planted a price target of $50 on the stock, representing 30% worth of upside to yesterday's close. So while momentum traders might be turned off by Clovis' sharp price decline in recent months, Klein's call could reflect a sense on Wall Street that its pipeline prospects are just too cheap to pass up.

Now what: According to Stifel, Clovis' risk/reward trade-off is rather attractive at this point. "Following the significant pull-back of ~60% from recent highs, we believe Clovis now presents with significant upside potential based on clinical and commercial prospects for CO-1686 in second-line EGFR-mutant NSCLC with T790M mutation," said Klein. "While we still remain conservative on approval timing and potential in earlier-stage disease, and note safety/tolerability concerns (particularly hyperglycemia), we view '1686 as a compelling and commercially viable, clinical candidate." So while Clovis remains just too speculative for average Fools, biotech-savvy contrarians might want to follow Stifel's lead.

More reliable ways to build wealth
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2984517, ~/Articles/ArticleHandler.aspx, 11/23/2014 11:23:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 17,810.06 91.06 0.51%
S&P 500 2,063.50 10.75 0.52%
NASD 4,712.97 11.10 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/21/2014 4:00 PM
CLVS $48.60 Down -2.19 -4.31%
CLOVIS ONCOLOGY IN… CAPS Rating: **

Advertisement